替诺福韦与拉夫米定对慢性乙型肝炎患者肝纤维化指标及炎症反应的影响  

Effects of tenofovir and lafmididine on hepatic fibrosis indexes and inflammatory reaction in patients with chronic hepatitis B

作　　者：顾明华 GU Ming-hua(Department of Infectious Diseases,Yangzhou Third People's Hospital,Yangzhou Jiangsu 225001,China)

机构地区：[1]扬州市第三人民医院感染科,江苏扬州225101

出　　处：《武警后勤学院学报（医学版）》2021年第9期34-36,共3页Journal of Logistics University of PAP（Medical Sciences）

摘　　要：【目的】探讨替诺福韦与拉夫米定对慢性乙型肝炎患者肝纤维化指标及炎症反应的影响。【方法】此次研究的80例慢性乙型肝炎患者均选取扬州市第三人民医院感染科,纳入时间为2017年1月至2020年7月,参考随机数字表法分为对照组与研究组,各40例。两组患者均给予常规护肝治疗,对照组在常规治疗基础上另外给予拉夫米定片口服治疗,研究组患者在常规治疗基础上给予富马酸丙酚替诺福韦片口服治疗,两组均治疗1年。比较两组患者治疗前后血清白细胞介素1(IL-1)、超敏C反应蛋白(hs-CRP)、可溶性细胞间黏附分子(sICAM-1)、透明质酸(HA)水平、IV型胶原(CIV)及层黏连蛋白(LN)水平。【结果】与治疗前比,研究组患者治疗后血清IL-1、hs-CRP、sICAM-1、HA、CIV、LN水平均呈降低趋势,且研究组均低于对照组(P<0.05)。【结论】替诺福韦联合拉夫米定治疗可有效改善慢性乙型肝炎患者肝纤维化程度,缓解机体炎症状态,减轻肝损伤,临床治疗效果显著。【Objective】To investigate the effects of tenofovir and lavmidine on liver fibrosis indexes and inflammation in patients with chronic hepatitis B.【Methods】The 80 patients with hepatitis B in this study were selected from the Department of Infectious Diseases,Yangzhou Third People’s Hospital,and the time was controlled between January 2017 and July 2020.The grouping method referred to the random number table method and divided into control group and study group,with 40 cases in each group.Both groups of patients were given conventional liver protection treatment.The control group was given lavmitine tablets orally on the basis of conventional liver protection treatment.Patients in the study group were given propofol tenofovir fumarate tablets orally on the basis of liver protection treatment,and both groups were treated for 1 year.The serum levels of interleukin-1(IL-1),high-sensitivity C-reactive protein(hs-CRP),soluble intercellular adhesion molecule(sICAM-1),hyaluronic acid(HA),IV collagen(CIV)and laminin(LN)were compared between the two groups before and after treatment.【Results】Compared with before treatment,serum IL-1,hs-CRP,sICAM-1,HA,CIV,and LN in the study group showed a decreasing trend after treatment.and the study group was lower than the control group(P<0.05).【Conclusion】Tenofovir combined with lavumidine treatment can effectively improve the degree of liver fibrosis in patients with chronic hepatitis B,alleviate the inflammatory state of the body,reduce the degree of liver damage in patients,and.significant clinical treatment effect.

关 键 词：慢性乙型肝炎 替诺福韦 拉夫米定 肝纤维化 炎症反应 

分 类 号：R512.6[医药卫生—内科学]